Compass Therapeutics, Inc. Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023; filed November 9, 2023. The unaudited statements are prepared under U.S. GAAP. Compass is a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics. It has no product revenue and remains dependent on equity financing and other capital sources.
Business Context and Development Status
- CTX-009: Phase 2 monotherapy trial in colorectal cancer and Phase 2/3 trial with paclitaxel in biliary tract cancer. The company expected first interim colorectal cancer data in the fourth quarter of 2023 and top-line biliary tract cancer data in the second half of 2024.
- CTX-471: Phase 1 combination trial with Merck’s KEYTRUDA. Dose escalation was completed in the third quarter with no dose-limiting toxicities observed; cohort expansion was expected to begin in the first quarter of 2024.
- CTX-8371: FDA cleared the IND in October 2023 following a third-quarter submission. The company planned to initiate a clinical trial in the fourth quarter of 2023.
- In January 2023, the company redirected internal research from early-stage discovery toward translational research and preclinical development support.
Financial Performance and Position
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $8.8 million vs. $9.8 million | $25.7 million vs. $20.1 million |
| General and administrative expense | $3.1 million vs. $2.8 million | $9.3 million vs. $8.7 million |
| Total operating expenses | $11.9 million vs. $12.6 million | $35.0 million vs. $28.8 million |
| Other income | $2.0 million vs. $0.6 million | $5.9 million vs. $1.1 million |
| Net loss | $10.0 million vs. $12.0 million | $29.1 million vs. $27.6 million |
| Basic and diluted loss per share | $0.08 vs. $0.12 | $0.23 vs. $0.27 |
| Net cash used in operating activities | Not separately provided | $28.3 million vs. $23.5 million |
All dollar amounts in the table are approximate and presented in millions; loss per share is shown as a positive magnitude for readability, while the filing reports losses of $(0.08) and $(0.23), respectively.
- At September 30, 2023, cash and cash equivalents were $30.4 million and marketable securities were $133.3 million, for total cash, cash equivalents and marketable securities of approximately $163.7 million.
- Total assets were $170.0 million, compared with $199.6 million at December 31, 2022. Total liabilities were $10.0 million, compared with $18.0 million at year-end 2022.
- The company reported no debt financing; liabilities consisted primarily of accounts payable, accrued expenses and operating lease obligations. Operating lease obligations totaled $2.0 million, including $1.2 million current and $0.9 million long term.
- Accumulated deficit was $301.9 million at September 30, 2023.
- Cash provided by investing activities was $20.7 million, primarily reflecting net sales and maturities of marketable securities. Financing activities provided $3.1 million, including approximately $3.0 million of net ATM proceeds.
Material Changes Versus the Prior Comparable Period
- Third-quarter R&D expense decreased 10%, primarily because $1.1 million of CTX-8371 toxicology spending incurred in the prior-year quarter did not recur. CTX-009 spending increased by approximately $0.3 million.
- Nine-month R&D expense increased 28%, driven primarily by $3.8 million of higher clinical costs and $1.3 million of higher personnel costs. CTX-009 spending increased by $9.6 million, while spending on CTX-471 and CTX-8371 declined by $2.8 million in aggregate.
- General and administrative expense increased 10% in the quarter and 7% year to date, primarily because of higher stock-based compensation.
- Net loss improved in the third quarter because lower operating expenses and higher interest income more than offset the increase in G&A expense. For the nine-month period, the net loss increased by $1.4 million despite $4.8 million of additional other income, reflecting higher operating expenses.
- Cash used in operating activities increased by $4.8 million year over year. The net change in cash improved substantially because the prior-year period included a large net purchase of marketable securities.
- Through September 30, 2023, the company sold 951,873 shares under its ATM agreement for $3.1 million of gross proceeds and approximately $3.0 million of net proceeds.
Guidance, Outlook, Risks and Unusual Items
- Management stated that cash, cash equivalents and marketable securities were expected to fund operating expenses and capital expenditures into 2026 based on current plans. The company also stated that additional funding will be required to complete clinical development, commercialize products if approved, and pursue potential in-licenses or acquisitions.
- Future financing may include equity, debt, collaborations, strategic alliances or licensing arrangements. Additional equity or convertible debt could dilute existing stockholders; debt or preferred financing could impose restrictive covenants or preferences.
- The company expects continued significant losses and expenses and does not expect near-term product revenue. Profitability depends on successful clinical development, regulatory approval and commercialization, none of which is assured.
- Clinical, manufacturing and regulatory execution remain material risks. The filing notes prior delays in sourcing selected supplies for clinical-trial materials and states that COVID-19-related effects may continue to affect trial timing.
- Under the ABL Bio agreement for CTX-009, potential future obligations include development and regulatory milestones, commercial milestones and tiered single-digit royalties. Accrued manufacturing expenses included $2.1 million of minimum contractual obligations related to CTX-009.
- The company disclosed up to $2.0 million of future potential milestone payments under its Adimab agreement; no milestone payments were made during 2023 through the reporting date.
- Stock-based compensation expense was $4.5 million for the first nine months, with $15.8 million of remaining unrecognized compensation cost.
- On November 8, 2023, the board approved a succession plan effective January 9, 2024: Vered Bisker-Leib is to become Chief Executive Officer, while Thomas Schuetz is to become President of Research and Development and Vice Chair of the board. Bisker-Leib is expected to join the board.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2023, and reported no material change in internal control over financial reporting during the quarter. No material legal proceedings were disclosed.
Important Facts for Investors to Verify
- Confirm enrollment progress, interim results and regulatory milestones for the CTX-009 colorectal and biliary tract cancer trials, including the expected 2024 top-line data.
- Assess whether the CTX-471 cohort expansion and CTX-8371 first-in-human program began on the stated timelines.
- Reconcile projected cash runway into 2026 against the company’s actual quarterly operating cash burn and planned clinical spending.
- Monitor additional capital requirements, ATM activity, dilution risk and any debt, collaboration or licensing transactions.
- Review the ABL Bio milestone, royalty and manufacturing obligations, as well as other contractual commitments.
- Evaluate clinical-trial supply, enrollment, safety, efficacy and regulatory risks, including any continuing effects from supply-chain or COVID-19 disruptions.
- Track the January 2024 management succession and any related changes to employment agreements or corporate strategy.